vs
FOSTER L B CO（FSTR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是FOSTER L B CO的1.4倍（$219.9M vs $160.4M），FOSTER L B CO净利率更高（1.5% vs -1.0%，领先2.5%），FOSTER L B CO同比增速更快（25.1% vs 2.0%），FOSTER L B CO自由现金流更多（$19.8M vs $16.8M），过去两年FOSTER L B CO的营收复合增速更高（13.6% vs 8.0%）
Foster L B Co.是一家总部位于美国的专业工业制造企业，主要生产销售工程通道产品、建筑组件及铁路基础设施用品，服务覆盖北美及部分全球地区的商业建筑、交通和工业领域客户。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FSTR vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$160.4M
营收增速更快
FSTR
高出23.1%
2.0%
净利率更高
FSTR
高出2.5%
-1.0%
自由现金流更多
FSTR
多$3.0M
$16.8M
两年增速更快
FSTR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $160.4M | $219.9M |
| 净利润 | $2.4M | $-2.2M |
| 毛利率 | 19.7% | 71.1% |
| 营业利润率 | 4.9% | 0.2% |
| 净利率 | 1.5% | -1.0% |
| 营收同比 | 25.1% | 2.0% |
| 净利润同比 | 1098.3% | 92.4% |
| 每股收益（稀释后） | $0.22 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSTROFIX
| Q4 25 | $160.4M | $219.9M | ||
| Q3 25 | $138.3M | $205.6M | ||
| Q2 25 | $143.6M | $203.1M | ||
| Q1 25 | $97.8M | $193.6M | ||
| Q4 24 | $128.2M | $215.7M | ||
| Q3 24 | $137.5M | $196.6M | ||
| Q2 24 | $140.8M | $198.6M | ||
| Q1 24 | $124.3M | $188.6M |
净利润FSTROFIX
| Q4 25 | $2.4M | $-2.2M | ||
| Q3 25 | $4.4M | $-22.8M | ||
| Q2 25 | $2.9M | $-14.1M | ||
| Q1 25 | $-2.1M | $-53.1M | ||
| Q4 24 | $-242.0K | $-29.1M | ||
| Q3 24 | $35.9M | $-27.4M | ||
| Q2 24 | $2.8M | $-33.4M | ||
| Q1 24 | $4.4M | $-36.0M |
毛利率FSTROFIX
| Q4 25 | 19.7% | 71.1% | ||
| Q3 25 | 22.5% | 72.2% | ||
| Q2 25 | 21.5% | 68.7% | ||
| Q1 25 | 20.6% | 62.8% | ||
| Q4 24 | 22.3% | 69.0% | ||
| Q3 24 | 23.8% | 68.7% | ||
| Q2 24 | 21.7% | 67.8% | ||
| Q1 24 | 21.1% | 67.5% |
营业利润率FSTROFIX
| Q4 25 | 4.9% | 0.2% | ||
| Q3 25 | 6.0% | -8.3% | ||
| Q2 25 | 5.3% | -7.9% | ||
| Q1 25 | -2.0% | -25.2% | ||
| Q4 24 | 2.4% | -5.3% | ||
| Q3 24 | 5.3% | -9.6% | ||
| Q2 24 | 3.2% | -12.5% | ||
| Q1 24 | 4.5% | -15.6% |
净利率FSTROFIX
| Q4 25 | 1.5% | -1.0% | ||
| Q3 25 | 3.1% | -11.1% | ||
| Q2 25 | 2.0% | -6.9% | ||
| Q1 25 | -2.2% | -27.4% | ||
| Q4 24 | -0.2% | -13.5% | ||
| Q3 24 | 26.1% | -13.9% | ||
| Q2 24 | 2.0% | -16.8% | ||
| Q1 24 | 3.6% | -19.1% |
每股收益（稀释后）FSTROFIX
| Q4 25 | $0.22 | $-0.05 | ||
| Q3 25 | $0.40 | $-0.57 | ||
| Q2 25 | $0.27 | $-0.36 | ||
| Q1 25 | $-0.20 | $-1.35 | ||
| Q4 24 | $-0.04 | $-0.76 | ||
| Q3 24 | $3.27 | $-0.71 | ||
| Q2 24 | $0.26 | $-0.88 | ||
| Q1 24 | $0.40 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3M | $82.0M |
| 总债务越低越好 | $42.6M | — |
| 股东权益账面价值 | $175.3M | $450.0M |
| 总资产 | $330.4M | $850.6M |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资FSTROFIX
| Q4 25 | $4.3M | $82.0M | ||
| Q3 25 | $3.4M | $62.9M | ||
| Q2 25 | $4.2M | $65.6M | ||
| Q1 25 | $2.6M | $58.0M | ||
| Q4 24 | $2.5M | $83.2M | ||
| Q3 24 | $3.1M | $30.1M | ||
| Q2 24 | $4.0M | $26.4M | ||
| Q1 24 | $3.1M | $27.0M |
总债务FSTROFIX
| Q4 25 | $42.6M | — | ||
| Q3 25 | $58.6M | $157.2M | ||
| Q2 25 | $81.4M | $157.0M | ||
| Q1 25 | $82.3M | $156.9M | ||
| Q4 24 | $46.8M | $157.0M | ||
| Q3 24 | $68.4M | $118.5M | ||
| Q2 24 | $87.0M | $118.0M | ||
| Q1 24 | $77.9M | $118.2M |
股东权益FSTROFIX
| Q4 25 | $175.3M | $450.0M | ||
| Q3 25 | $174.8M | $442.5M | ||
| Q2 25 | $174.4M | $458.3M | ||
| Q1 25 | $170.8M | $458.3M | ||
| Q4 24 | $178.3M | $503.1M | ||
| Q3 24 | $181.9M | $525.9M | ||
| Q2 24 | $147.1M | $546.0M | ||
| Q1 24 | $144.6M | $570.3M |
总资产FSTROFIX
| Q4 25 | $330.4M | $850.6M | ||
| Q3 25 | $333.9M | $832.6M | ||
| Q2 25 | $349.9M | $837.2M | ||
| Q1 25 | $342.8M | $823.1M | ||
| Q4 24 | $334.6M | $893.3M | ||
| Q3 24 | $344.5M | $867.9M | ||
| Q2 24 | $333.3M | $882.0M | ||
| Q1 24 | $326.4M | $906.0M |
负债/权益比FSTROFIX
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.33× | 0.36× | ||
| Q2 25 | 0.47× | 0.34× | ||
| Q1 25 | 0.48× | 0.34× | ||
| Q4 24 | 0.26× | 0.31× | ||
| Q3 24 | 0.38× | 0.23× | ||
| Q2 24 | 0.59× | 0.22× | ||
| Q1 24 | 0.54× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | $16.8M |
| 自由现金流率自由现金流/营收 | 12.3% | 7.6% |
| 资本支出强度资本支出/营收 | 1.5% | 4.9% |
| 现金转化率经营现金流/净利润 | 9.18× | — |
| 过去12个月自由现金流最近4个季度 | $25.2M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FSTROFIX
| Q4 25 | $22.2M | $27.7M | ||
| Q3 25 | $29.2M | $12.4M | ||
| Q2 25 | $10.4M | $11.6M | ||
| Q1 25 | $-26.1M | $-18.4M | ||
| Q4 24 | $24.3M | $23.7M | ||
| Q3 24 | $24.7M | $11.7M | ||
| Q2 24 | $-5.0M | $9.0M | ||
| Q1 24 | $-21.4M | $-18.6M |
自由现金流FSTROFIX
| Q4 25 | $19.8M | $16.8M | ||
| Q3 25 | $26.4M | $2.5M | ||
| Q2 25 | $7.7M | $4.5M | ||
| Q1 25 | $-28.7M | $-25.1M | ||
| Q4 24 | $22.3M | $15.2M | ||
| Q3 24 | $21.7M | $6.3M | ||
| Q2 24 | $-7.0M | $-360.0K | ||
| Q1 24 | $-24.2M | $-29.1M |
自由现金流率FSTROFIX
| Q4 25 | 12.3% | 7.6% | ||
| Q3 25 | 19.1% | 1.2% | ||
| Q2 25 | 5.4% | 2.2% | ||
| Q1 25 | -29.4% | -13.0% | ||
| Q4 24 | 17.4% | 7.0% | ||
| Q3 24 | 15.8% | 3.2% | ||
| Q2 24 | -5.0% | -0.2% | ||
| Q1 24 | -19.4% | -15.4% |
资本支出强度FSTROFIX
| Q4 25 | 1.5% | 4.9% | ||
| Q3 25 | 2.0% | 4.8% | ||
| Q2 25 | 1.9% | 3.5% | ||
| Q1 25 | 2.6% | 3.5% | ||
| Q4 24 | 1.5% | 4.0% | ||
| Q3 24 | 2.2% | 2.7% | ||
| Q2 24 | 1.5% | 4.7% | ||
| Q1 24 | 2.2% | 5.6% |
现金转化率FSTROFIX
| Q4 25 | 9.18× | — | ||
| Q3 25 | 6.70× | — | ||
| Q2 25 | 3.61× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | -1.74× | — | ||
| Q1 24 | -4.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSTR
| Rail Technologies And Services Segment | $98.0M | 61% |
| Over Time Output Method | $26.3M | 16% |
| Services | $19.4M | 12% |
| Rail Technologies Products | $10.0M | 6% |
| Over Time Input Method | $8.3M | 5% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
